COVID-19: External Quality Assurance Program Oversight Laboratory (EQAPOL)

NIH Pandemic-Era Grants

Pandemic Era Grants

2023

↗ Live URL (may be dead)

Document text

Principal Investigator: THOMAS  DENNY
Organization: DUKE UNIVERSITY
Fiscal Year: 2023
Award: $1,830,201
Funding agency: National Institute of Allergy and Infectious Diseases

The mission of the Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), is to increase basic knowledge of the pathogenesis and transmission of the human immunodeficiency virus (HIV), support the development of therapies for HIV infection and its complications, and support the development of vaccines and other prevention strategies. Reliable laboratory data are essential to the clinical evaluation of candidate HIV vaccine platforms and immunogens. Data from multiple laboratories performing assays in support of single or multiple vaccine candidate trials must be accurate and reproducible. The purpose of the External Quality Assurance Program Oversight Laboratory (EQAPOL) is to provide confidence that individual laboratories generate reliable data to support HIV vaccine immunogen advancement. EQAPOL supports these efforts by participating in the development and availability of validated assays, providing common and well-characterized reagents and Standard Operating Procedures (SOPs), and providing External Quality Assurance (EQA) programs to measure and monitor laboratory performance. This project will provide external quality assurance program support for laboratories performing immunology assays for COVID-19 Prevention Network (CoVPN)-led vaccine efficacy trials.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><AIDS><AIDS Virus><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immuno-Deficiency Syndrome><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Acquired Immunologic Deficiency Syndrome><Antigens><Assay><Binding><Bioassay><Biologic Assays><Biological Assay><Biometrics><Biometry><Biostatistics><COVID-19><COVID-19 Prevention Network><COVID-19 antibody><COVID-19 assay><COVID-19 virus><COVID19><COVID19 assay><COVID19 virus><CV-19><CV19><Clinical Evaluation><Clinical Testing><CoV-2><CoV2><CoVPN><Data><Development><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><HIV><HIV Infections><HIV vaccine><HIV/AIDS Vaccines><HTLV-III Infections><HTLV-III-LAV Infections><Human Immunodeficiency Viruses><Human T-Lymphotropic Virus Type III Infections><Immunology><Immunology procedure><Individual><Knowledge><LAV-HTLV-III><Laboratories><Lymphadenopathy-Associated Virus><Measures><Mission><Molecular Interaction><Monitor><NIAID><NIH><National Institute of Allergy and Infectious Disease><National Institutes of Health><Pathogenesis><Performance><Preventative strategy><Prevention strategy><Preventive strategy><Procedures><Reagent><Reproducibility><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 antibody><SARS-CoV-2 assay><SARS-CoV2><SARS-CoV2 antibody><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome related corona virus 2><Staining method><Stains><Transmission><United States National Institutes of Health><Virus-HIV><Wuhan coronavirus><antibody against COVID-19><antibody against SARS-CoV-2><antibody against SARS-CoV2><antibody against coronavirus disease 2019><antibody against severe acute respiratory syndrome coronavirus 2><antibody to COVID-19><antibody to SARS-CoV-2><antibody to SARS-CoV2><antibody to coronavirus disease 2019><antibody to severe acute respiratory syndrome coronavirus 2><clinical test><corona virus disease 2019><coronavirus disease 2019><coronavirus disease 2019 antibody><coronavirus disease 2019 assay><coronavirus disease 2019 prevention network><coronavirus disease 2019 virus><coronavirus disease-19><coronavirus disease-19 virus><coronavirus infectious disease-19><cytokine><data management><data quality><depository><design><designing><develop a vaccine><develop therapy><develop vaccines><development of a vaccine><developmental><efficacy trial><flow cytophotometry><hCoV19><human immunodeficiency virus vaccine><immunogen><immunologic assay><immunologic assay/test><intervention development><nCoV2><programs><quality assurance><repository><research clinical testing><severe acute respiratory syndrome coronavirus 2 antibody><severe acute respiratory syndrome coronavirus 2 assay><therapy development><transmission process><treatment development><vaccine candidate><vaccine development><vaccine efficacy><vaccine platform>